Zacks: Analysts Anticipate Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE:ZOM) Will Announce Earnings of -$0.01 Per Share

Wall Street analysts expect that Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE:ZOM) will post earnings per share of ($0.01) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Zomedica Pharmaceuticals Corp (NYSEAMERICAN)’s earnings. Zomedica Pharmaceuticals Corp (NYSEAMERICAN) posted earnings per share of ($0.02) in the same quarter last year, which indicates a positive year over year growth rate of 50%. The company is scheduled to report its next quarterly earnings report on Thursday, August 13th.

On average, analysts expect that Zomedica Pharmaceuticals Corp (NYSEAMERICAN) will report full-year earnings of ($0.04) per share for the current fiscal year. For the next financial year, analysts expect that the firm will report earnings of ($0.03) per share. Zacks Investment Research’s earnings per share averages are an average based on a survey of research analysts that follow Zomedica Pharmaceuticals Corp (NYSEAMERICAN).

Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE:ZOM) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.02) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.02).

ZOM has been the topic of several research analyst reports. HC Wainwright reissued a “buy” rating and issued a $0.50 price target (down from $0.65) on shares of Zomedica Pharmaceuticals Corp (NYSEAMERICAN) in a report on Wednesday, June 17th. Zacks Investment Research upgraded shares of Zomedica Pharmaceuticals Corp (NYSEAMERICAN) from a “hold” rating to a “buy” rating and set a $0.25 target price on the stock in a research report on Saturday, June 20th.

In other Zomedica Pharmaceuticals Corp (NYSEAMERICAN) news, Director Johnny D. Powers bought 625,000 shares of the firm’s stock in a transaction on Tuesday, July 7th. The shares were purchased at an average price of $0.16 per share, for a total transaction of $100,000.00. Following the transaction, the director now directly owns 625,000 shares in the company, valued at approximately $100,000. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 51.80% of the company’s stock.

A hedge fund recently bought a new stake in Zomedica Pharmaceuticals Corp (NYSEAMERICAN) stock. Clear Creek Financial Management LLC bought a new stake in Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE:ZOM) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 400,000 shares of the company’s stock, valued at approximately $95,000. Clear Creek Financial Management LLC owned approximately 0.37% of Zomedica Pharmaceuticals Corp (NYSEAMERICAN) at the end of the most recent reporting period. Hedge funds and other institutional investors own 11.77% of the company’s stock.

Zomedica Pharmaceuticals Corp (NYSEAMERICAN) stock opened at $0.16 on Tuesday. Zomedica Pharmaceuticals Corp has a twelve month low of $0.11 and a twelve month high of $0.50. The company’s 50-day moving average price is $0.19 and its two-hundred day moving average price is $0.20.

About Zomedica Pharmaceuticals Corp (NYSEAMERICAN)

Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. The company's lead drug product candidate is ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs.

Recommended Story: Gross Domestic Product (GDP)

Get a free copy of the Zacks research report on Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (ZOM)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Zomedica Pharmaceuticals Corp (NYSEAMERICAN) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zomedica Pharmaceuticals Corp (NYSEAMERICAN) and related companies with's FREE daily email newsletter.